Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
Pharma Officials Air Hopes and Concerns for New LDP Leader, Eyes on MHLW Revamp
To read the full story
Related Article
- New Digital, Administrative Reform Minister Set to Break Silos, Propel Healthcare Revamp
October 6, 2021
- Economic Security Chief Vows to Beef Up Vaccine Development, Manufacturing in Japan
October 6, 2021
- Master Plan on COVID-19 Measures to Be Compiled Relatively Soon: Response Minister
October 6, 2021
- New Vaccine Czar Hints Booster Program Could Start in December
October 6, 2021
- Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
October 6, 2021
- PM Kishida Orders 3 Ministers to Map Out Overall COVID-19 Response Plan
October 5, 2021
- New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
- All 4 Contenders in LDP Leadership Race Vow to Expand COVID-19 Measures
September 21, 2021
- LDP Leadership Candidates Eye Reorganization of Ministries and Agencies, Key Focus on MHLW
September 16, 2021
REGULATORY
- LDP Lawmakers Call for Penalties against “Dump and Run Away” Generic Makers
March 29, 2024
- Beni-Koji Issue: MHLW Requests Self-Inspections to Purchasers of Kobayashi’s Red Rice Yeast
March 29, 2024
- Label Revision Ordered for CAR-T Therapies to Add New Precaution
March 29, 2024
- Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
March 29, 2024
- Japan Diet Passes FY2024 Budget, Record Social Security Spending
March 29, 2024
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…